Matthias Wymann

USPTO Granted Patents = 5 (Patent Applications = 6)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 9)

Average Co-Inventor Count = 6.0

ph-index = 3

Forward Citations = 34(Granted Patents)

Company Filing History:

2 out of 4

Piqur Therapeutics Ag

Applied Research Systems Ars Holding N.v.

patents

where one patent can have more than one assignee

Years Active: 2007-2021

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11186591 - Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines (2021-11-30),

2. 10640516 - Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines (2020-05-05),

3. 9556203 - Conformationally restricted P13K and mTOR inhibitors (2017-01-31),

4. 8921361 - Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes (2014-12-30),

5. 7157239 - Method and kit for identifying and/or quantifying radiolabeled aminoglycoside binding molecules (2007-01-02),

Title: Matthias Wymann: Innovator in Pharmaceutical Chemistry

Introduction

Matthias Wymann is a notable inventor based in Bern, Switzerland. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for therapeutic applications. With a total of five patents to his name, Wymann's work focuses on innovative solutions for treating disorders mediated by lipid kinases.

Latest Patents

Wymann's latest patents include the invention of difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines. These compounds are classified as phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), and PI3K-related kinase (PIKKs) inhibitors. The compounds are characterized by a specific formula, wherein certain components are nitrogen or carbon-based, with the requirement that at least two of these components are nitrogen. These innovative compounds are designed to be effective either alone or in combination with other therapeutic agents for treating various disorders.

Career Highlights

Throughout his career, Matthias Wymann has worked with prominent organizations, including Piqur Therapeutics AG and Universität Basel. His experience in these institutions has allowed him to advance his research and contribute to the development of groundbreaking pharmaceutical solutions.

Collaborations

Wymann has collaborated with esteemed colleagues such as Vladimir C

This text is generated by artificial intelligence and may not be accurate.